Abstract
The cysteinyl leukotrienes—leukotriene C4(LTC4), leukotriene D4(LTD4) and leukotriene E4(LTE4)—are important mediators of human bronchial asthma1,2,3,. Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT1 and CysLT2 (refs 4,5,6). The CysLT1-selective antagonists, such as montelukast (Singulair)7,8,9,10, zafirlukast (Accolate)11 and pranlukast (Onon)12, are important in the treatment of asthma. Previous biochemical characterization of CysLT1 antagonists and the CysLT1 receptor has been in membrane preparations from tissues enriched for this receptor13. Here we report the molecular and pharmacological characterization of the cloned human CysLT1 receptor. We describe the functional activation (calcium mobilization) of this receptor by LTD4 and LTC4, and competition for radiolabelled LTD4 binding to this receptor by the cysteinyl leukotrienes and three structurally distinct classes of CysLT1-receptor antagonists. We detected CysLT1-receptor messenger RNA in spleen, peripheral blood leukocytes and lung. In normal human lung, expression of the CysLT1-receptor mRNA was confined to smooth muscle cells and tissue macrophages. Finally, we mapped the human CysLT1-receptor gene to the X chromosome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dahlen, S. E., Hedqvist, P., Hammarstrom, S. & Samuelsson, B. Leukotrienes are potent constrictors of human bronchi. Nature 288, 484–486 (1980).
Piper, P. J. Formation and actions of leukotrienes. Physiol. Rev. 64, 744–761 (1984).
Lewis, R. A., Austen, K. F. & Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323, 645–655 (1990).
Coleman, R. A. et al. Prostanoid and leukotriene receptors. A progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandins Thromboxane Leukotriene Res. 23, 283–285 (1995).
Charette, L. & Jones, T. J. Effects of L-serine borate on antagonism of leukotriene C4-induced contractions of guinea pig trachea. Br. J. Pharmacol. 91, 179–188 (1987).
Labat, C. et al. Asecond cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 263, 800– 805 (1992).
Jones, T. R. et al. Pharmacology of montelukast sodium (SINGULAIRTM), a potent and selective leukotriene D4receptor antagonist. Can. J. Physiol. Pharmacol. 73, 191– 201 (1995).
Reiss, T. F. et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158, 1213–1220 ( 1998).
Knorr, B. et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. J. Am. Med. Assoc. 279, 1181–1186 (1998).
Leff, J. A. et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339, 147–152 ( 1998).
Suissa, S. et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild–moderate asthma. Ann. Int. Med. 126, 177–183 (1997).
Grossman, J. et al. Results of the first U.S. double-blind, placebo-controlled multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J. Asthma 34, 321– 328 (1997).
Metters, K. M. & Zamboni, R. J. Photoaffinity labeling of the leukotriene D4receptor in guinea pig lung. J. Biol. Chem. 268, 6487–6495 (1993).
Yokomizo, T., Izumi, T., Change, K., Takuwa, Y. & Shimizu, T. AG-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620–624 (1997).
Martin, V. et al. Leukotriene binding, signaling and analysis of HIV coreceptor function in mouse and human leukotriene B4 receptor transfected cells. J. Biol. Chem. 274, 8597–8603 (1999).
Pearson, W. R. & Lipman, D. J. Improved tools for biological sequence comparison. Proc. Natl Acad. Sci. USA 85, 2444–2448 (1988).
Ellis, C. et al. EP874047A2: cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor.Eur. Patent Applic. EP0874047A2 (1998).
Chan, C. et al. Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists. J. Pharmacol. Exp. Ther. 269, 891–896 ( 1994).
Jones, T. R. et al. Pharmacology of L-660,711 (MK-571): a novel, potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 67, 17–28 ( 1989).
McClintock, T. S., Rising, J. P. & Lerner, M. R. Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP-dependent protein kinase and protein kinase C. J. Cell. Physiol. 167, 1–7 (1996).
Potenza, M. N., Graminiski, G. F., Schmaus, C. & Lerner, M. R. Functional expression and characterization of human D2 an dD3 dopamine receptors. J. Neurosci. 14, 1463– 1476 (1994).
Frey, E. A. et al. Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. Eur. J. Pharmacol. 244, 239–250 (1993).
Metters, K. M. Leukotriene receptors. J. Lipid Mediat. 12, 413–427 (1995).
Durieux, M. E., Carlisle, S. J., Salafranca, M. N. & Lynch, K. R. Endogenous responses to sphingosine-1-phosphate in X. laevis oocytes: similarities with lysophosphatidic acid signaling. Am. J. Physiol. 264, C1360–C1364 ( 1993).
Hooks, S. B. et al. Characterization of a receptor subtype-selective lysophosphatidic acid mimetic. Mol. Pharmacol. 53, 188– 194 (1998).
Kolakowski, L. F. J et al. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J. Neurosci. 71, 2239–2251 (1998).
Ungrin, M. D. et al. An automated aequorin luminescence-based functional calcium assay for G-protein coupled receptors. Anal. Biochem.(in the press).
Wright, D. H., Metters, K. M., Abramovitz, M. & Ford-Hutchinson, A. W. Characterization of the recombinant prostanoid DP receptor and identification of L-644,698, a novel DP agonist. Br. J. Pharmacol. 123, 1317–1324 (1998).
Acknowledgements
The authors thank M. E. Durieux (Dept. Anesthesiology, Univ. Virginia) for the use of his laboratory's oocyte recording equipment, D. Pettibone and R. Gould (Dept. Pharmacology, Merck & Co., West Point, Pennsylvania) for support to the MRL orphan GPCR project, and K. Clark for preparation of the figures. This work was supported in part by grants to K.R.L. from the National Institutes of Health. This paper is dedicated to the late P. J. Piper for her pioneering work in the pharmacological characterization of the cysteinyl leukotrienes.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lynch, K., O'Neill, G., Liu, Q. et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399, 789–793 (1999). https://doi.org/10.1038/21658
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/21658
This article is cited by
-
The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
Cell Communication and Signaling (2023)
-
A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action
Journal of Cell Communication and Signaling (2022)
-
Mechanistic insight on the role of leukotriene receptors in ischemic–reperfusion injury
Pharmacological Reports (2021)
-
Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms
Molecular Diversity (2021)
-
Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
Acta Neuropathologica Communications (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.